Pulmonary Hypertension 


Pulmonary hypertension (PH) is an increase of blood pressure in the pulmonary arterypulmonary vein, or pulmonary capillaries, together known as the lung vasculature, leading to shortness of breathdizzinessfaintingleg swelling and other symptoms.

An increasing number of patients are undergoing home therapy for the treament of Pulmonary Hypertension. This is a critical application which requires the maximum of safety and reliability. 

The continuous IV infusions used to treat pulmonary arterial hypertension are FlolanRemodulin, and Veletri. A small pump is commonly used to infuse these medications. The pump is carried on the patient at all times. Many patients use the standard carrying case issued with the pump for every day use but other patients have created their own systems for carrying their pumps. 


Treatments for Pulmonary Hypertension

FLOLAN (Epoprostenol)

Epoprostenol is an intravenous medication approved for the treatment of pulmonary arterial hypertension (PAH) in World Health Organization (WHO) Group 1 patients. Epoprostenol is a synthetic analogue of prostacyclin, a naturally occurring substance in the body, which has effects on dilating blood vessels. Epoprostenol was approved for PAH by the United States Food and Drug Administration (FDA) in 1995.


VELETRI (Epoprostenol)

Veletri (Epoprostenol for Injection) is an intravenous prostacyclin. Unlike other epoprostenol formulations approved for PAH, this formulation is stable at room temperature (77 F, 25 °C).

Regardless of concentration Veletri is stable at room temperature for up to 48 hours immediately upon reconstitution and dilution, or for up to 24 hours after refrigerated storage (2-8 °C) for up to 8 days, making the use of frozen gel packs unnecessary.

Veletri can be reconstituted with either Sterile Water for Injection, or Sodium Chloride 0.9% Injection, eliminating the need for drug-specific diluents.


REMODULIN (Treprostinil)

Remodulin is indicated for the treatment of pulmonary arterial hypertension. It may be administered as a continuous subcutaneous infusion or continuous intravenous infusion; however, because of the risks associated with chronic indwelling central venous catheters, including serious blood stream infections, continuous intravenous infusion should be reserved for patients who are intolerant of the subcutaneous route, or in whom these risks are considered warranted.

In patients with pulmonary arterial hypertension requiring transition from epoprostenol sodium (Flolan), treprostinil is indicated to diminish the rate of clinical deterioration. The risks and benefits of each drug should be carefully considered prior to transition.

Copyright © 2014 - Hemoglobe15 Hellas. Designed by φi